<DOC>
	<DOCNO>NCT01473173</DOCNO>
	<brief_summary>The objective study : - To evaluate safety tolerability single multiple oral dos CJ-12420 healthy male subject . - To evaluate single- multiple-dose PK orally administer CJ-12420 healthy male subject . - To evaluate single- multiple-dose PD orally administer CJ-12420 healthy male subject . - To compare multiple-dose pharmacodynamics ( PD ) orally administer CJ-12420 esomeprazole healthy male subject .</brief_summary>
	<brief_title>Safety , Tolerability , PK , PD Escalating Single Multiple Oral Doses CJ-12420 Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Male volunteer age 20 45 year old ( inclusive ) Body mass index ( BMI ) range 19 28 kg/m2 weigh least 50 kg Medically healthy clinically significant vital sign ( sit position blood pressure , pulse rate ) ( 90 mmHg ≤ systolic blood pressure ≤ 140 mmHg , 50 mmHg ≤ diastolic blood pressure ≤ 95 mmHg , 45 beat per minute ≤ pulse rate ≤ 95 beat per minute ) Nonsmokers nonusers nicotinecontaining product least 3 month History clinically significant gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , immunologic , psychiatric , musculoskeletal cardiovascular disease condition , , opinion Investigator , would jeopardize safety subject impact validity study result History allergy sensitivity drug , include prior serious adverse reaction PPIs ( e.g . omeprazole , rabeprazole , lansoprazole ) History symptomatic GERD , erosive esophagitis , duodenal ulcer , gastric ulcer , Barrett 's esophagus ZollingerEllison syndrome , previous positive H. pylorus</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>